Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co LtdfiledCriticalEisai R&D Man Co Ltd
Publication of NZ812760ApublicationCriticalpatent/NZ812760A/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
Provided herein are methods of reducing clinical decline in a subject having early Alzheimer’s disease, methods of converting an amyloid positive subject having early Alzheimer’s disease to amyloid negative, methods of reducing brain amyloid level in a subject, and methods of preventing Alzheimer’s disease, the methods comprising administering a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody. In some embodiments, the subject is ApoE4-positive. In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401.
NZ812760A2018-07-242019-07-23Methods of treatment and prevention of alzheimer’s disease
NZ812760A
(en)
high activity pancreatin, a process for the preparation of aa pancreatin having specific lipase activity of at least approximately 120 usp iu / mg and method of treating a patient subject to a pathological condition associated with pandreatic enzyme insufficiency